Home  /  Resource Library  /  Single-agent rituximab and ultra-low-dose adaptive radiotherapy for the treatment of indolent B-cell non-Hodgkin lymphomas

Single-agent rituximab and ultra-low-dose adaptive radiotherapy for the treatment of indolent B-cell non-Hodgkin lymphomas

Results of a study investigating rituximab with radiation therapy for treatment of indolent lymphomas.